Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Rare Diseases

Recurrence

Leukemia

Leukemia, Lymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Leukemia, B-Cell

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Chronic Lymphocytic Leukemia

All Drugs and Chemicals

Antineoplastic Agents

Amino Acids

Ibrutinib

Idelalisib

Ricolinostat

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Histone Deacetylase Inhibitors

Tyrosine

ACY-1215 and Ibrutinib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.

ACY-1215 and Idelalisib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.

ACY-1215

Jennifer B Brown, MD, PhD

This research study is studying a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

This research study is a Phase I clinical trial. The investigators are studying the combination of the B-cell receptor (BCR) pathway inhibitors with ricolinostat, in order to try to enhance both the initial remission and to help improve the response in those who relapse after a first inhibitor and are receiving a second.

The FDA (the U.S. Food and Drug Administration) has not approved ACY-1215 as a treatment for any disease. ACY-1215 or ricolinostat is a histone deacetylase inhibitor, specifically HDAC6. The FDA has approved idelalisib as well as ibrutinib as treatment options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

A Phase Ib Study of ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed Chronic Lymphocytic Leukemia

Acetylon Pharmaceuticals Incorporated

Dana-Farber Cancer Institute

MD, PhD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL	NCT02787369	Recurrent Chron...	ACY-1215 Ibrutinib Idelalisib	18 Years -	Dana-Farber Cancer Institute
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL	NCT02787369	Recurrent Chron...	ACY-1215 Ibrutinib Idelalisib	18 Years -	Dana-Farber Cancer Institute
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL	NCT02787369	Recurrent Chron...	ACY-1215 Ibrutinib Idelalisib	18 Years -	Dana-Farber Cancer Institute

Spots Global Cancer Trial Database for recurrent chronic lymphoid leukemia